Abstract
There is an urgent need for the identification of commonly assessable predictive factors in the treatment of patients with metastatic breast cancer. During the course of a treatment including low dose metronomic oral cyclophosphamide and capecitabine plus i.v. bevacizumab (plus erlotinib in one third of the patients) for metastatic breast cancer, we observed that a relevant number of patients developed repeatedly elevated levels of mean corpuscular volume (MCV) of red blood cells without a significant fall in hemoglobin levels. We conducted a retrospective analysis on these 69 patients to evaluate if the increase in MCV could be associated to tumor response. During the course of treatment 42 out of 69 patients (61%) developed macrocytosis. Using Cox proportional hazards modeling that incorporated macrocytosis (MCV ≥ 100 fl) as a time-dependent covariate, macrocytosis resulted in a halved risk of disease progression (HR 0.45; 95% CI, 0.22-0.92, p-value 0.028). In a landmark analysis limited to patients with no sign of progression after 24 weeks of treatment, median time to progression was 72 weeks (48 weeks after landmark) in patients who had developed macrocytosis, and 43 weeks (19 weeks after landmark) in patients who had not ...Continue Reading
References
Nov 7, 1991·The New England Journal of Medicine·H B MussR L Capizzi
Dec 10, 1987·The New England Journal of Medicine·A CoatesG Gill
Sep 1, 1972·British Journal of Haematology·A V Hoffbrand, A H Waters
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R K GregoryS Ashley
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Apr 28, 2000·Biometrics·T R Ten HaveM K James
Sep 3, 2002·Computer Methods and Programs in Biomedicine·Rodolphe ThiébautDaniel Commenges
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Aug 4, 2004·American Journal of Clinical Oncology·Constantine J KarvellasJohn R Mackey
Jul 12, 2008·Cancer·Brian I RiniRonald M Bukowski
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia DellapasquaMarco Colleoni
Citations
Sep 27, 2012·Journal of Mammary Gland Biology and Neoplasia·Robert S Kerbel
Jun 11, 2014·Nature Reviews. Clinical Oncology·Nicolas AndréEddy Pasquier
Sep 17, 2014·Biomarkers in Medicine·Gemma CramarossaUrban Emmenegger
Apr 24, 2012·The Breast : Official Journal of the European Society of Mastology·Cagatay Arslan, Kadri Altundag
Oct 17, 2015·Anti-cancer Drugs·Michela RobertoPaolo Marchetti
Aug 8, 2015·The Tohoku Journal of Experimental Medicine·Xuan HongQingyong Xu
Aug 5, 2015·Nature Reviews. Clinical Oncology·Elisabetta Munzone, Marco Colleoni
Apr 26, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Oktay BozkurtMetin Ozkan
Apr 15, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sebastiano ButiAndrea Ardizzoni
Jul 8, 2014·Cancer Treatment Reviews·Emilia MontagnaMarco Colleoni
Oct 19, 2016·Nature Reviews. Clinical Oncology·Guido Bocci, Robert S Kerbel
May 11, 2018·Gastroenterology Research and Practice·Wen-Yi ZhangChang-Lin Zou
Sep 10, 2020·Cancer Management and Research·Ke-Jie LiZheng-Hua Fei
Jul 6, 2017·Anti-cancer Drugs·Tihana Boraska JelavićEduard Vrdoljak
Jan 16, 2018·Technology in Cancer Research & Treatment·Yu-Jen ChenChen-Hsi Hsieh
Aug 10, 2018·Scientific Reports·Chew-Teng KorPing-Fang Chiu
Sep 7, 2021·Anti-cancer Drugs·Tihana Boraska JelavićEduard Vrdoljak